BLUE DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important May 28 Deadline in Securities Class Action – BLUE May 21, 2024 10:46AM
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Blue May 15, 2024 01:15PM
BLUE LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE Apr 30, 2024 11:59AM
ROSEN, LEADING INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE Apr 27, 2024 09:47AM
ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE Apr 18, 2024 05:46PM
View Older Stories

Apr 15, 2024 06:09PM ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
Apr 7, 2024 05:28PM ROSEN, A LONGSTANDING LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE
Apr 5, 2024 06:38PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
Apr 2, 2024 05:45PM ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
Mar 29, 2024 06:33PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
Nov 8, 2021 08:50AM Pre-Open Stock Movers 11/08: (AUTL) (TTD) (BLNK) Higher; (EHTH) (BLUE) (TSLA) Lower (more...)
Jul 28, 2021 06:59AM Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
May 19, 2021 05:00PM Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel
Apr 29, 2021 06:59AM Bristol Myers Squibb Reports First Quarter Financial Results for 2021
Mar 29, 2021 06:29AM Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Announces FDA Approval for Abecma for Relapsed or Refractory Multiple Myeloma
Mar 26, 2021 10:59PM U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Mye
Feb 4, 2021 06:59AM Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
Dec 5, 2020 12:30PM Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020
Dec 4, 2020 08:03AM Magenta Therapeutics (MGTA), bluebird bio Inc. (BLUE) Report Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145
Dec 4, 2020 08:00AM Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Ce
Nov 5, 2020 06:59AM Bristol Myers Squibb Reports Third Quarter 2020 Financial Results
Sep 22, 2020 07:00AM Bristol Myers Squibb (BMY), bluebird (BLUE) Announce FDA Accepts for Priority Review Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleuce
Sep 22, 2020 06:59AM U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)
Jul 29, 2020 04:20PM Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Announce Submission of BLA to FDA for Idecabtagene Vicleucel for Adults with R/R Multiple Myeloma
Jul 29, 2020 04:16PM Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple My
May 13, 2020 05:06PM Bristol Myers Squibb (BMY) and bluebird bio (BLUE) to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in R/R Multiple Myeloma Patients at ASCO20
May 13, 2020 05:00PM Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20
May 13, 2020 07:00AM Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Provide Regulatory Update on Idecabtagene Vicleucel for Treatment of Patients with MM, BLA Requires Further Detail
May 13, 2020 06:59AM Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma
Mar 31, 2020 07:00AM Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Announce Submission of BLA for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel to FDA
Mar 31, 2020 06:59AM Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA
Jan 16, 2020 11:10AM UPDATE: Axalta (AXTA) Viewed as Most Likely Takeover Target in Survey of M&A Desks - Bloomberg
Dec 10, 2019 05:58AM bluebird bio (BLUE), Bristol-Meyers Squibb (BMY) Highlight Updated Data from Ongoing Ph. 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma
Dec 9, 2019 06:15PM bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and
Dec 6, 2019 04:17PM Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Announce Positive Top-line Results from Pivotal Phase 2 KarMMa Study of Ide-cel in R/R Multiple Myeloma
Dec 6, 2019 04:16PM Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
Oct 9, 2019 08:03AM bluebird bio (BLUE), Novo Nordisk (NVO) Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases
Oct 9, 2019 08:00AM bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases
Dec 3, 2018 05:55AM bluebird bio (BLUE), Celgene Corp. (CELG) Report Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217
Dec 2, 2018 07:30PM bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myel
Dec 1, 2018 05:00PM bluebird bio Presents Updated Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent β-Thalassemia and Sickle Cell Disease at 60th Annual Meeting of the American Society of H
Aug 6, 2018 06:31AM Regeneron (REGN), bluebird bio (BLUE) Announce Pact to Discover, Develop and Commercialize New Cell Therapies for Cancer
Aug 6, 2018 06:30AM bluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer
Aug 6, 2018 06:30AM Regeneron and bluebird bio Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer
Jan 22, 2018 09:29AM Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)
Nov 23, 2016 09:24AM Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)
Oct 14, 2016 08:30AM Cancer Immunotherapy ETF Celebrates One-Year Anniversary
Sep 8, 2016 09:29AM Pre-Open Stock Movers 09/08: (RPRX) (RAD) (JUNO) Higher; (GEVO) (NLST) (TSCO) (PIR) Lower (more...)
Aug 3, 2016 04:05PM bluebird bio Reports Second Quarter 2016 Financial Results and Recent Operational Progress
Jun 14, 2016 11:25AM Goldman M&A Basket in Focus After Predicting LinkedIn (LNKD); (TWTR) (BLUE) (TRIP), Others Added
May 4, 2016 04:05PM bluebird bio Reports First Quarter 2016 Financial Results and Recent Operational Progress
Feb 25, 2016 04:06PM bluebird bio (BLUE) CFO DeTore Resigns; Successor Named
Feb 25, 2016 04:05PM bluebird bio Announces Transition of Chief Financial Officer
Feb 24, 2016 04:05PM bluebird bio Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Operational Progress
Nov 4, 2015 04:09PM bluebird bio Reports Third Quarter 2015 Financial Results and Recent Operational Progress
View Older Stories